R O Brady, J N Kanfer, R M Bradley, D Shapiro
Year: | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2001 | 2000 | 1999 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1986 | 1985 | 1984 | 1983 | 1982 | 1981 | 1980 | 1979 | 1978 | 1977 | 1976 | 1975 | 1974 | 1973 | 1972 | 1971 | 1970 | 1969 | 1968 | 1967 | 1966 | 1960 | Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Citations: | 3 | 4 | 4 | 6 | 6 | 9 | 19 | 17 | 9 | 3 | 13 | 5 | 8 | 6 | 11 | 12 | 4 | 2 | 7 | 10 | 7 | 4 | 7 | 3 | 1 | 3 | 3 | 1 | 1 | 3 | 4 | 1 | 4 | 1 | 1 | 3 | 1 | 2 | 4 | 3 | 3 | 1 | 3 | 2 | 5 | 8 | 3 | 8 | 9 | 8 | 9 | 7 | 10 | 7 | 7 | 3 | 1 | 1 | 310 |
Title and authors | Publication | Year |
---|---|---|
Roscoe O. Brady: Physician whose pioneering discoveries in lipid biochemistry revolutionized treatment and understanding of lysosomal diseases
JM Aerts, TM Cox |
Blood Cells, Molecules, and Diseases | 2017 |
Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes
WW Kallemeijn, S Scheij, S Hoogendoorn, MD Witte, DH Chao, CP van Roomen, R Ottenhoff, HS Overkleeft, RG Boot, JM Aerts, A Dardis |
PloS one | 2017 |
Altered Differentiation Potential of Gaucher’s Disease iPSC Neuronal Progenitors due to Wnt/β-Catenin Downregulation
O Awad, LM Panicker, RM Deranieh, MP Srikanth, RA Brown, A Voit, T Peesay, TS Park, ET Zambidis, RA Feldman |
Stem Cell Reports | 2017 |
Stabilization of Glucocerebrosidase by Active Site Occupancy
FB Bdira, WW Kallemeijn, SV Oussoren, S Scheij, B Bleijlevens, BI Florea, CP van Roomen, R Ottenhoff, MJ van Kooten, MT Walvoort, MD Witte, RG Boot, M Ubbink, HS Overkleeft, JM Aerts |
ACS chemical biology | 2017 |
Treatment of profound thrombocytopenia in a patient with Gaucher disease type 1: Is there a role for substrate reduction therapy
CI Ha, S DeArmey, H Cope, M Rairikar, PS Kishnani |
Molecular Genetics and Metabolism Reports | 2017 |
Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems
K Okamoto, T Nakashima, M Shinohara, T Negishi-Koga, N Komatsu, A Terashima, S Sawa, T Nitta, H Takayanagi |
Physiological reviews | 2017 |
The metabolism of glucocerebrosides — From 1965 to the present
AH Futerman, FM Platt |
Molecular Genetics and Metabolism | 2017 |
Enrichment of apoplastic fluid with therapeutic recombinant protein for efficient biofarming
A Chatterjee, NC Das, S Raha, IB Maiti, A Shrestha, A Khan, S Acharya, N Dey |
Biotechnology Progress | 2017 |
Long-term response in biochemical markers of bone turnover during enzyme replacement therapy in a case-series of patients with Gaucher disease type I from Northern Greece
E Vargiami, M Dimitriadou, M Economou, A Christoforidis, D I Zafeiriou |
Hippokratia | 2017 |